April 10, 2025
Find Therapeutics Welcomes Two New Members to Its Board of Directors
Dr. Nancy Messier and Dr. Thierry Abribat join Find Therapeutics to support its missionand growth.
MONTRÉAL, Canada, April 10, 2025 – Find Therapeutics Inc., a biopharmaceuticalcompany dedicated to the development of innovative therapies for autoimmunediseases, is proud to announce the appointment of two scientific and life scienceexperts to its Board of Directors: Dr. Nancy Messier and Dr. Thierry Abribat.
“We are pleased to welcome Dr. Nancy Messier and Dr. Thierry Abribat to our Board ofDirectors. Their complementary expertise — in drug discovery, clinical development,and business strategy — is a valuable asset to Find as we continue advancing ourremyelinating agent, FTX-101” commented Paul F. Truex, Chairman of Find, “As FTX101 nears completion of initial human clinical studies, Nancy and Thierry will beinvaluable at helping guide our next steps. The novel mechanism of FTX-101 representsa promising approach for a variety of autoimmune diseases where repairing andrebuilding myelin could be a monumental change for patients. We are fortunate tohave their expertise and look forward to their contributions.”
As Vice President of Drug Discovery at Feldan Therapeutics,Dr. Messier oversees drug discovery and preclinicaldevelopment of innovative therapies using the Shuttle, apeptide-based intracellular delivery platform. Her work onthe intralesional treatment of basal cell carcinoma has ledto a first clinical trial in humans in the fall of 2024. Dr.Messier obtained a PhD in microbiology from LavalUniversity following her work on antibiotic resistanceconducted at the Infectious Disease Research Center(CHUQ) in Quebec City.
Dr. Abribat is a biotech executive and serial entrepreneurwho has founded, managed, and exited three biotechcompanies, delivering innovative drugs to the patients whileconsistently providing positive returns to investors: AlizéPharma, acquired by Millendo Therapeutics (2017); AlizéPharma 2, acquired by Jazz Pharmaceuticals (2016); andAmolyt Pharma, acquired by AstraZeneca (2024). Prior to hisentrepreneurial track, he held several executive positionswith increasing responsibilities in drug development,business development and management, as CSO at Theratechnologies (TSX:TH,Montreal, Canada) and as COO at OPi SA, Pharmaceuticals for Rare Diseases (Lyon, France), until OPi’s acquisition by EUSA Pharma Inc in 2007. Dr. Abribat is a doctor inveterinary medicine and holds a PhD in neuroendocrinology from the NationalPolytechnic Institute of Toulouse.
About FTX-101
Find's lead compound, FTX-101, is a first-in-class remyelinagng agent that aims torestore vision to people suffering from Chronic Opgc Neuropathy. FTX-101 is a ragonallydesigned therapeugc pepgde that targets Plexin A1 and Neuropilin 1, a receptorcomplex present in the brain that has been shown to be involved in the migragon anddifferengagon of oligodendrocyte precursor cells into myelinagng oligodendrocytes.Compelling preclinical data for FTX-101 in demyelinagng models show strong myelinrepair acgvity.
About Find
Find Therapeugcs is clinical-stage biopharmaceugcal company dedicated to thedevelopment of next generagon therapiesto treat inflammatory autoimmune diseases.The company was launched in 2020 and is supported with investments from CTI LifeSciences, adMare BioInnovagons and Invesgssement Québec, with an exclusive licensefrom SATT-Conectus and the University of Strasbourg on technology and related knowhow. Visit www.findtherapeutics.com for more details about Find Therapeutics.
Investor Contact:
Investor@findtherapeugcs.com
514-665-7322
